ZeClinics

Executive Summary

ZeClinics is a contract research organization (CRO) based in Barcelona, Spain, specializing in zebrafish-based preclinical research. Founded in 2013, the company leverages CRISPR genome editing and zebrafish models to provide tailored solutions for disease modeling, target validation, and phenotypic drug screening. By bridging the gap between cell-based assays and mammalian models, ZeClinics aims to accelerate early-stage drug discovery and reduce costs. With a team of 201-500 employees, the company serves pharmaceutical and biotechnology clients, offering services that include efficacy and safety testing. Its unique platform enables rapid, cost-effective in vivo studies, positioning ZeClinics as a key player in the preclinical CRO market, particularly for complex genetic disorders and drug delivery applications.

Upcoming Catalysts (preview)

• Q3 2026Launch of new in vivo screening service for rare diseases70% success
• Q4 2026Partnership with a top-20 pharmaceutical company for drug discovery collaboration50% success
• H2 2026Series A funding announcement to expand operations and technology platform60% success